Search Results - "Nordquist, Luke T."

Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer by SCHER, Howard I, XIAOYU JIA, MELUCH, Anthony A, NORDQUIST, Luke T, VENNER, Peter M, HEIDENREICH, Axel, CHU, Luis, HELLER, Glenn, CHI, Kim, DE WIT, Ronald, BERRY, William R, ALBERS, Peter, HENICK, Brian, WATERHOUSE, David, RUETHER, Dean J, ROSEN, Peter J

“…To compare the efficacy and safety of docetaxel plus high-dose calcitriol (DN-101) to docetaxel plus prednisone in an open-label phase III trial. Nine hundred…”
Get full text

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer by Montgomery, Bruce, Eisenberger, Mario A, Rettig, Matthew B, Chu, Franklin, Pili, Roberto, Stephenson, Joseph J, Vogelzang, Nicholas J, Koletsky, Alan J, Nordquist, Luke T, Edenfield, William J, Mamlouk, Khalid, Ferrante, Karen J, Taplin, Mary-Ellen

“…Galeterone is a selective, multitargeted agent that inhibits CYP17, antagonizes the androgen receptor (AR), and reduces AR expression in prostate cancer cells…”
Get full text

Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung by Nordquist, Luke T, Simon, George R, Cantor, Alan, Alberts, W Michael, Bepler, Gerold

“…Adenocarcinoma of the lung is now the most common histologic subtype of lung cancer in the United States. To determine if there are survival differences in…”
Get more information

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer by Sartor, Oliver, de Bono, Johann, Chi, Kim N, Fizazi, Karim, Herrmann, Ken, Rahbar, Kambiz, Tagawa, Scott T, Nordquist, Luke T, Vaishampayan, Nitin, El-Haddad, Ghassan, Park, Chandler H, Beer, Tomasz M, Armour, Alison, Pérez-Contreras, Wendy J, DeSilvio, Michelle, Kpamegan, Euloge, Gericke, Germo, Messmann, Richard A, Morris, Michael J, Krause, Bernd J

“…Guiding the beta-emitting isotope lutetium-177 to prostate cancer lesions with the prostate-specific membrane antigen–targeted radioligand 177 Lu-PSMA-617 plus…”
Get full text

Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study by Yu, Evan Y., Piulats, Josep M., Gravis, Gwenaelle, Fong, Peter C.C., Todenhöfer, Tilman, Laguerre, Brigitte, Arranz, Jose A., Oudard, Stephane, Massard, Christophe, Heinzelbecker, Julia, Nordquist, Luke T., Carles, Joan, Kolinsky, Michael P., Augustin, Marinela, Gurney, Howard, Tafreshi, Ali, Li, Xin Tong, Qiu, Ping, Poehlein, Christian H., Schloss, Charles, de Bono, Johann S.

“…The KEYNOTE-365 study assessed the efficacy and safety of pembrolizumab combination therapies in metastatic castration-resistant prostate cancer (mCRPC). In…”
Get full text

Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study by Saad, Fred, Hussain, Maha H.A., Tombal, Bertrand, Fizazi, Karim, Sternberg, Cora N., Crawford, E. David, Nordquist, Luke T., Bögemann, Martin, Tutrone, Ronald, Shore, Neal D., Belkoff, Laurence, Fralich, Todd, Jhaveri, Jay, Srinivasan, Shankar, Li, Rui, Verholen, Frank, Kuss, Iris, Smith, Matthew R.

“…Darolutamide led to deep and durable prostate-specific antigen (PSA) responses and a higher proportion of patients with undetectable PSA in comparison to…”
Get full text

Correlation analyses of radiographic progression‐free survival with clinical and health‐related quality of life outcomes in metastatic castration‐resistant prostate cancer: Analysis of the phase 3 VISION trial by Morris, Michael J., de Bono, Johann, Nagarajah, James, Sartor, Oliver, Wei, Xiao X., Nordquist, Luke T., Koshkin, Vadim S., Chi, Kim N., Krause, Bernd J., Herrmann, Ken, Rahbar, Kambiz, Vickers, Adrian, Mirante, Osvaldo, Ghouse, Ray, Fizazi, Karim, Tagawa, Scott T.

“…Background [177Lu]Lu–PSMA‐617 (177Lu‐PSMA‐617) plus protocol‐permitted standard of care (SOC) prolonged overall survival (OS) and radiographic progression‐free…”
Get full text

Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer by Higano, Celestia S., Armstrong, Andrew J., Sartor, A. Oliver, Vogelzang, Nicholas J., Kantoff, Philip W., McLeod, David G., Pieczonka, Christopher M., Penson, David F., Shore, Neal D., Vacirca, Jeffrey, Concepcion, Raoul S., Tutrone, Ronald F., Nordquist, Luke T., Quinn, David I., Kassabian, Vahan, Scholz, Mark C., Harmon, Matt, Tyler, Robert C., Chang, Nancy N., Tang, Hong, Cooperberg, Matthew R.

“…Background The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated…”
Get full text

Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26] by Yu, Evan Y., Piulats, Josep M., Gravis, Gwenaelle, Fong, Peter C.C., Todenhöfer, Tilman, Laguerre, Brigitte, Arranz, Jose A., Oudard, Stephane, Massard, Christophe, Heinzelbecker, Julia, Nordquist, Luke T., Carles, Joan, Kolinsky, Michael P., Augustin, Marinela, Gurney, Howard, Tafreshi, Ali, Li, Xin Tong, Qiu, Ping, Poehlein, Christian H., Schloss, Charles, de Bono, Johann S.

Get full text

Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases by Sartor, Oliver, Heinrich, Daniel, Mariados, Neil, Méndez Vidal, Maria José, Keizman, Daniel, Thellenberg Karlsson, Camilla, Peer, Avivit, Procopio, Giuseppe, Frank, Stephen J., Pulkkanen, Kalevi, Rosenbaum, Eli, Severi, Stefano, Trigo, José, Trandafir, Lucia, Wagner, Volker, Li, Rui, Nordquist, Luke T.

“…Background Radium‐223 dichloride (radium‐223) is approved for patients with castration‐resistant prostate cancer (CRPC), symptomatic bone metastases, and no…”
Get full text

Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer by Gupta, Shilpa, Nordquist, Luke T., Fleming, Mark T., Berry, William R., Zhang, Jingsong, Ervin, Sharon L., Eisner, Joel R., Baskin-Bey, Edwina S., Shore, Neal D.

“…Abstract Purpose: Seviteronel (INO-464) is a selective cytochrome P450c17a (CYP17) 17,20-lyase (lyase) and androgen receptor (AR) inhibitor with antitumor…”
Get full text

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer by Sartor, Oliver, de Bono, Johann, Chi, Kim N., Fizazi, Karim, Herrmann, Ken, Rahbar, Kambiz, Tagawa, Scott T., Nordquist, Luke T., Vaishampayan, Nitin, El-Haddad, Ghassan, Park, Chandler H., Beer, Tomasz M., Armour, Alison, Pérez-Contreras, Wendy J., DeSilvio, Michelle, Kpamegan, Euloge, Gericke, Germo, Messmann, Richard A., Morris, Michael J., Krause, Bernd J.

Get full text

Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data by Higano, Celestia S., Armstrong, Andrew J., Sartor, Oliver, Vogelzang, Nicholas J., Kantoff, Philip W., McLeod, David G., Pieczonka, Christopher M., Penson, David F., Shore, Neal D., Vacirca, Jeffrey, Concepcion, Raoul S., Tutrone, Ronald F., Nordquist, Luke T., Quinn, David I., Kassabian, Vahan, Scholz, Mark C., Harmon, Matt, Tyler, Robert C., Chang, Nancy N., Tang, Hong, Cooperberg, Matthew R.

Get full text

eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer by Shore, Neal D., Tutrone, Ronald F., Mariados, Neil F., Nordquist, Luke T., Mehlhaff, Bryan A., Steere, Karyn J., Harrelson, Stacey S.

“…This is the first study to prospectively evaluate the combined use of radium-223 dichloride and a novel oral hormonal therapy, abiraterone acetate, in men with…”
Get full text

Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF by Aggarwal, Rahul R, Beer, Tomasz M, Weinberg, Vivian K, Higano, Celestia, Taplin, Mary-Ellen, Ryan, Charles J, Lin, Amy M, Alumkal, Joshi, Graff, Julie N, Nordquist, Luke T, Herrera, Isheen, Small, Eric J

“…Micro-Abstract Docetaxel improves survival in metastatic castration-resistant prostate cancer (mCRPC) but chemotherapy resistance is universal. In the current…”
Get full text

DNA vaccines: an active immunization strategy for prostate cancer by Wolchok, Jedd D, Gregor, Polly D, Nordquist, Luke T, Slovin, Susan F, Scher, Howard I

“…Immunotherapy is currently being investigated as a treatment for patients with asymptomatic, recurrent prostate cancer manifested only by a rising…”
Get full text

Octreotide for gastrointestinal bleeding of obscure origin in an anticoagulated patient by Nordquist, Luke T, Wallach, Paul M

Get full text

SABRE: Assessment of safety and efficacy of 64 Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer by Nordquist, Luke T., Lengyelova, Eva, Iagaru, Andrei, Mancini, Brandon Robert, Song, Hong, Osman, Medhat, Josephson, David, Almaguel, Frankis, Saltzstein, Daniel, Parker, Michelle, Miller, Robert M., Shore, Neal D.

“…TPS346 Background: Between 20-40% of patients with prostate cancer (PC) will relapse within 10 years of their primary PC treatment, as identified through…”
Get full text

COMBAT: A study of 64 Cu-SAR-BBN and 67 Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer by Nordquist, Luke T., Lengyelova, Eva, Almaguel, Frankis, Mancini, Brandon Robert, Song, Hong, Armstrong, Andrew J., Zurita, Amado J., Anderson, Monique, Parker, Michelle, Miller, Robert M., Iagaru, Andrei

“…TPS247 Background: Metastatic castrate resistant prostate cancer (mCRPC) is an advanced and lethal form of prostate cancer. Prostate-specific membrane antigen…”
Get full text

SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67 Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer by Johnson, Geoffrey, Lengyelova, Eva, Nordquist, Luke T., Prasad, Vikas, Anderson, Monique, Gervasio, Othon, Parker, Michelle, Miller, Robert M., Sartor, A. Oliver, Tagawa, Scott T.

“…TPS246 Background: Prostate cancer (PC) is common and despite recent advances in treatment options, patients with metastatic disease still have poor outcomes,…”
Get full text